Neumonía grave por COVID-19 y administración de medicamentos biológicos.
Saved in:
| Title: | Neumonía grave por COVID-19 y administración de medicamentos biológicos. |
|---|---|
| Alternate Title: | Severe pneumonia due to COVID-19 and administration of biological drugs. |
| Authors: | Carlos Herrera-García, José1,2 jchg10@yahoo.com.mx, Nuche-Salazar, N. Patricia2,3, Domínguez-Peregrina, Alfredo2,4, Reyes, Roberto2,4, Arizpe-Bravo, Bertha2,5 |
| Source: | Medicina Interna de México. Nov/Dic2020, Vol. 36 Issue 6, p888-894. 7p. |
| Abstract (English): | BACKGROUND: In February 2020 World Health Organization (WHO) declared a pandemic for COVID-19 disease (coronavirus disease 2019). In the treatment, the evidence suggests the use of biological medications to counteract the so-called cytochemical storm in order to decrease systemic inflammation and therefore reduce morbidity and mortality. CLINICAL CASES: Six patients (four male, 66.6% and two women, 33.3%) with average age of 58.1 years (range: 41-71) with diagnosis of severe pneumonia due to COVID-19 and the administration of two implied treatments in the cytochemical storm, such as tocilizumab and ruxolitinib. This paper described their clinical evolution in an intensive care unit of a private hospital of Puebla, Puebla. The most important findings were: relieve at 48 hours in the clinical parameters and reduction of inflammation markers after the application of biological drugs. There were not adverse reactions. CONCLUSIONS: The use of tocilizumab, ruxolitinib or both are medications that reduced systemic inflammation in patients with severe pneumonia due to COVID-19. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | ANTECEDENTES: En febrero de 2020 la Organización Mundial de la Salud (OMS) declaró pandemia por enfermedad COVID-19 (coronavirus disease 2019). En el tratamiento la evidencia sugiere la administración de medicamentos biológicos para contrarrestar la llamada tormenta citoquímica con la finalidad de disminuir la inflamación sistémica y, por consiguiente, reducir la morbilidad y mortalidad. CASOS CLÍNICOS: Seis pacientes (4 varones, 66.6% y 2 mujeres, 33.3%) con promedio de edad de 58.1 años (intervalo: 41-71) con diagnóstico de neumonía grave por COVID-19 y administración de dos tratamientos implicados en la tormenta citoquímica, como tocilizumab y ruxolitinib. Se describe su evolución clínica en una unidad de terapia intensiva de un hospital privado de la ciudad de Puebla, Puebla. Los hallazgos más importantes fueron: mejoría a las 48 horas en los parámetros clínicos y disminución de los marcadores de inflamación tras la aplicación de los biológicos. No se obtuvieron reacciones adversas. CONCLUSIONES: Tocilizumab, ruxolitinib o ambos son medicamentos que alivian la inflamación sistémica en los pacientes con neumonía grave por COVID-19. [ABSTRACT FROM AUTHOR] |
| Copyright of Medicina Interna de México is the property of Colegio de Medicina Interna de Mexico and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 147122900 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Neumonía grave por COVID-19 y administración de medicamentos biológicos. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Severe pneumonia due to COVID-19 and administration of biological drugs. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Carlos+Herrera-García%2C+José%22">Carlos Herrera-García, José</searchLink><relatesTo>1,2</relatesTo><i> jchg10@yahoo.com.mx</i><br /><searchLink fieldCode="AR" term="%22Nuche-Salazar%2C+N%2E+Patricia%22">Nuche-Salazar, N. Patricia</searchLink><relatesTo>2,3</relatesTo><br /><searchLink fieldCode="AR" term="%22Domínguez-Peregrina%2C+Alfredo%22">Domínguez-Peregrina, Alfredo</searchLink><relatesTo>2,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Reyes%2C+Roberto%22">Reyes, Roberto</searchLink><relatesTo>2,4</relatesTo><br /><searchLink fieldCode="AR" term="%22Arizpe-Bravo%2C+Bertha%22">Arizpe-Bravo, Bertha</searchLink><relatesTo>2,5</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Medicina+Interna+de+México%22">Medicina Interna de México</searchLink>. Nov/Dic2020, Vol. 36 Issue 6, p888-894. 7p. – Name: Abstract Label: Abstract (English) Group: Ab Data: BACKGROUND: In February 2020 World Health Organization (WHO) declared a pandemic for COVID-19 disease (coronavirus disease 2019). In the treatment, the evidence suggests the use of biological medications to counteract the so-called cytochemical storm in order to decrease systemic inflammation and therefore reduce morbidity and mortality. CLINICAL CASES: Six patients (four male, 66.6% and two women, 33.3%) with average age of 58.1 years (range: 41-71) with diagnosis of severe pneumonia due to COVID-19 and the administration of two implied treatments in the cytochemical storm, such as tocilizumab and ruxolitinib. This paper described their clinical evolution in an intensive care unit of a private hospital of Puebla, Puebla. The most important findings were: relieve at 48 hours in the clinical parameters and reduction of inflammation markers after the application of biological drugs. There were not adverse reactions. CONCLUSIONS: The use of tocilizumab, ruxolitinib or both are medications that reduced systemic inflammation in patients with severe pneumonia due to COVID-19. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: ANTECEDENTES: En febrero de 2020 la Organización Mundial de la Salud (OMS) declaró pandemia por enfermedad COVID-19 (coronavirus disease 2019). En el tratamiento la evidencia sugiere la administración de medicamentos biológicos para contrarrestar la llamada tormenta citoquímica con la finalidad de disminuir la inflamación sistémica y, por consiguiente, reducir la morbilidad y mortalidad. CASOS CLÍNICOS: Seis pacientes (4 varones, 66.6% y 2 mujeres, 33.3%) con promedio de edad de 58.1 años (intervalo: 41-71) con diagnóstico de neumonía grave por COVID-19 y administración de dos tratamientos implicados en la tormenta citoquímica, como tocilizumab y ruxolitinib. Se describe su evolución clínica en una unidad de terapia intensiva de un hospital privado de la ciudad de Puebla, Puebla. Los hallazgos más importantes fueron: mejoría a las 48 horas en los parámetros clínicos y disminución de los marcadores de inflamación tras la aplicación de los biológicos. No se obtuvieron reacciones adversas. CONCLUSIONES: Tocilizumab, ruxolitinib o ambos son medicamentos que alivian la inflamación sistémica en los pacientes con neumonía grave por COVID-19. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Medicina Interna de México is the property of Colegio de Medicina Interna de Mexico and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=147122900 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.24245/mim.v36i6.4551 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 7 StartPage: 888 Titles: – TitleFull: Neumonía grave por COVID-19 y administración de medicamentos biológicos. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Carlos Herrera-García, José – PersonEntity: Name: NameFull: Nuche-Salazar, N. Patricia – PersonEntity: Name: NameFull: Domínguez-Peregrina, Alfredo – PersonEntity: Name: NameFull: Reyes, Roberto – PersonEntity: Name: NameFull: Arizpe-Bravo, Bertha IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: Nov/Dic2020 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 01864866 Numbering: – Type: volume Value: 36 – Type: issue Value: 6 Titles: – TitleFull: Medicina Interna de México Type: main |
| ResultId | 1 |
